RX100 Rescues Life if Administered 3, 6, 12, or Up to 24 Hours After Exposure to Lethal, Whole-Body Radiation!
JOHNSON CITY, Tenn., May 24, 2007 /PRNewswire/ -- RxBio, Inc., announces that its lead product, RX100, a potent radioprotectant as well as radiomitigator, protects against lethal, whole-body radiation when administered before, during, or up to 24 hours after exposure. Animal studies convincingly demonstrate that RX100 can prevent death if given before or during lethal radiation exposure -- and rescue life if administered up to 24 hours after lethal, whole-body radiation exposure -- although maximum benefit is derived if the product is administered within 6-12 hours following exposure.
Dr. W. Shannon McCool, RxBio's CEO, points out that: "RX100 is unique among radioprotectants/radiomitigators in that it boosts natural mechanisms that promote and sustain cell survival in almost every cell type and at the same time inhibits the cascade leading to programmed cell death (apoptosis). Thus, RX100 augments the good and shuts down the bad. While other products shut down essential cellular signaling mechanisms involved in radiation- induced cellular injury and tend to lack specificity and/or may be toxic, RX100 is a specific activator of natural, nontoxic, protective mechanisms of cell survival and antiapoptosis. Among its actions, RX100 is protecting critical stem cells. RX100 is a specific activator of natural, nontoxic, protective mechanisms of cell survival. RX100 can be formulated for a wide range of patient types -- from infants to the elderly -- and can be administered either orally or subcutaneously."
In addition, RX100 is a potent protector of the GI tract -- whether administered subcutaneously or orally. RxBio scientists have developed an oral formulation that though not absorbed systemically, provides significant protection to the gut from radiation, chemotherapy, and other toxic substances. Among other things, it prevents the disintegration of the mucosal barrier -- thus, preventing diarrhea and overwhelming bacterial infections, potentially severe side effects from such exposures.
Several agencies of the Federal Government continue their interest in this promising new compound and its unique approach and mechanism.
CONTACT: W. Shannon McCool, D.Ph., of RxBio, Inc., +1-423-928-3330, fax:+1-423-282-6602, smccool@rxbio.com
Web site: http://www.rxbio.com/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
Posted: May 2007
